* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Posters – Infectious diseases and Vaccines NAME OF THE
Survey
Document related concepts
Trimeric autotransporter adhesin wikipedia , lookup
Antimicrobial surface wikipedia , lookup
Marine microorganism wikipedia , lookup
Traveler's diarrhea wikipedia , lookup
Infection control wikipedia , lookup
Clostridium difficile infection wikipedia , lookup
Transmission (medicine) wikipedia , lookup
Carbapenem-resistant enterobacteriaceae wikipedia , lookup
Magnetotactic bacteria wikipedia , lookup
Bacterial cell structure wikipedia , lookup
Disinfectant wikipedia , lookup
Methicillin-resistant Staphylococcus aureus wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Human microbiota wikipedia , lookup
Bacterial morphological plasticity wikipedia , lookup
Transcript
Posters – Infectious diseases and Vaccines NAME OF THE PROJECT NAME OF THE MAIN CONTACT ORGANISATION NAME PEPSTAF Clément Jouanneau SATT OUEST VALORISATION Context: The emergence of multi-drug resistance in bacteria seems to be one of the most issue in human health. In this context, S aureus and Gram negative infections are the worst case, because of these abilities to bypass immune system and to resist against many antibiotics. Issue: The society, both in the community and the hospitals, needs novel antibiotics, and finding new drugs active on the ESKAPE bacteria has stalled for years because it is notoriously difficult Technology Solution: Scientists have demonstrated that bacterial toxins might be an attractive starting point for antibacterial drug development. Indeed, bactericidal, cyclic pseudopeptides were inferred from an S. aureus toxin, and they elicit elevated stability in human serum. Their activity is against Gram-negative and -positive bacteria without erythrocyte toxicity; They induce bacterial envelope remodeling with vesicle-like bodies. The technology developed by research team uses a toxic peptide which have been chemically modified (cyclization, introduction of analogues), allowing bacterial death while avoiding hemolytic activity against human cells and we have considerably increased their half-lifes in human sera. Our latest results indicated a higher efficiency, compared to Vancomycin, of some peptides on various resistant strains (IMC of around 1µM) Customers / Target market Industry and competitors Financing need / Commercial opportunity IP – Patent situation Human health: - Nosocomial diseases - Multi-drug resistances : S. aureus (MRSA, VISA), E. coli, ESKAPE bacteria Animal health: - Bovine Mastitis, a major issue for milk collect For MRSA market, the main competitors, with their product Linezolid and Cubicin, are Pfizer and Cubist (Merck). 17% of S.aureus Strains found in hospital are MRSA. 9% of E.coli strains found in hospital are C3G resistant. Data from WHO global Report on Surveillance AMR 2014 EP patent Priority data: 10/31/2014 PCT filed on 2015 Future steps / Milestones Further reading In vivo Toxicity and efficiency studies are on going Looking for an industrial partnership: Clinical trial is the next step to validate the concept in human Competitive advantages : - Natural mechanism - Reduce production cost (peptide length = 7aa) Membrane location and action, expecting low resistance levels Therapeutic Index up to 200 Publications: “Converting a S.aureus Toxin into effective cyclic pseudopeptide antibiotics” Solecki et al., 2015, Chemestry & Biology 22, 1-7 Contact person Clément Jouanneau, Technology Transfer [email protected] 1/2 Officer, SATT Ouest Valorisation,